| 2026-05-28 |
详情>>
内部人交易：
ROTHBLATT MARTINE A等共交易23笔
|
| 2026-05-06 |
详情>>
股本变动：
变动后总股本4244.67万股
|
| 2026-05-06 |
详情>>
业绩披露：
2026年一季报每股收益6.32美元,归母净利润2.75亿美元,同比去年增长-14.68%
|
| 2026-05-06 |
财报披露：
美东时间 2026-05-06 盘前发布财报
|
| 2026-04-29 |
股东大会：
将于2026-06-26召开股东大会
会议内容 ▼▲
- 1.Election of the twelve directors named in this Proxy Statement
2.Advisory resolution to approve executive compensation
3.Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan
4.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026
|
| 2026-02-25 |
详情>>
业绩披露：
2025年年报每股收益30.13美元,归母净利润13.35亿美元,同比去年增长11.68%
|
| 2026-02-25 |
详情>>
业绩披露：
2023年年报每股收益21.04美元,归母净利润9.85亿美元,同比去年增长35.40%
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益21.76美元,归母净利润9.70亿美元,同比去年增长8.57%
|
| 2025-09-02 |
复牌提示：
2025-09-02 06:55:00 停牌，复牌日期 2025-09-02 07:30:00
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益14.04美元,归母净利润6.32亿美元,同比去年增长8.04%
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益7.18美元,归母净利润3.22亿美元,同比去年增长5.09%
|
| 2025-04-29 |
股东大会：
将于2025-06-26召开股东大会
会议内容 ▼▲
- 1.Election of the twelve directors named in this Proxy Statement
2.Advisory resolution to approve executive compensation
3.Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan
4.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2025
|
| 2025-02-26 |
详情>>
业绩披露：
2024年年报每股收益26.44美元,归母净利润11.95亿美元,同比去年增长21.35%
|
| 2025-02-26 |
详情>>
业绩披露：
2022年年报每股收益15.98美元,归母净利润7.27亿美元,同比去年增长52.86%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益19.73美元,归母净利润8.94亿美元,同比去年增长16.43%
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益12.79美元,归母净利润5.85亿美元,同比去年增长16.92%
|
| 2024-05-01 |
详情>>
业绩披露：
2024年一季报每股收益6.52美元,归母净利润3.07亿美元,同比去年增长27.27%
|
| 2024-04-29 |
股东大会：
将于2024-06-26召开股东大会
会议内容 ▼▲
- 1.Election of the twelve directors named in this Proxy Statement
2.Advisory resolution to approve executive compensation
3.Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan
4.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2024
|
| 2023-04-28 |
股东大会：
将于2023-06-26召开股东大会
会议内容 ▼▲
- 1.Election of the twelve directors named in this Proxy Statement.
2.Advisory resolution to approve executive compensation.
3.Advisory vote on the frequency of future advisory votes on executive compensation.
4.Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.
5.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2023.
|
| 2022-04-29 |
股东大会：
将于2022-06-27召开股东大会
会议内容 ▼▲
- 1.Election of the nine directors named in this Proxy Statement
2.Advisory resolution to approve executive compensation
3.Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan
4.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2022
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-19 |
股东大会：
将于2021-09-30召开股东大会
会议内容 ▼▲
- 1.Approval of an amendment to our Restated Certificate of Incorporation to become a public benefit corporation
|
| 2021-04-29 |
股东大会：
将于2021-06-25召开股东大会
会议内容 ▼▲
- 1.Election of the five directors named in the Proxy Statement
2.Advisory resolution to approve executive compensation
3.Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan
4.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2021
|
| 2020-04-29 |
股东大会：
将于2020-06-26召开股东大会
会议内容 ▼▲
- 1.Election of the three directors named in the Proxy Statement
2.Approval of an amendment to our Amended and Restated Certificate of Incorporation to declassify our Board of Directors and provide for the annual election of our directors
3.Advisory resolution to approve executive compensation
4.Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan
5.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2020
|
| 2019-04-29 |
股东大会：
将于2019-06-26召开股东大会
会议内容 ▼▲
- 1.To elect the four Class II directors named in the Proxy Statement and nominated by our Board of Directors to serve three-year terms until the 2022 annual meeting of shareholders and until their successors are duly elected and qualified or until their office is otherwise vacated;
2.To vote on an advisory resolution to approve executive compensation;
3.To approve the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2019;
5.To consider a shareholder proposal requesting declassification of our Board of Directors, if properly presented;
6.To consider and act upon such other business as may properly come before the annual meeting of shareholders and any adjournment or postponement thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-26召开股东大会
会议内容 ▼▲
- 1.To elect the four Class I directors named in the Proxy Statement and nominated by our Board of Directors to serve three-year terms until the 2021 annual meeting of shareholders and until their successors are duly elected and qualified or until their office is otherwise vacated;
2.To vote on an advisory resolution to approve executive compensation;
3.To approve the amendment and restatement of the United Therapeutics Corporation 2015 Stock Incentive Plan;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2018;
5.To consider and act upon such other business as may properly come before the annual meeting of shareholders and any adjournment or postponement thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-28召开股东大会
会议内容 ▼▲
- 1.To elect the three Class III directors named in the Proxy Statement and nominated by our Board of Directors to serve three-year terms until the 2020 annual meeting of shareholders and until their successors are duly elected and qualified or until their office is otherwise vacated;
2.To vote on an advisory resolution to approve executive compensation;
3.To vote on the frequency of future advisory votes to approve executive compensation;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2017;
5.To consider and act upon such other business as may properly come before the annual meeting of shareholders and any adjournment or postponement thereof.
|